Anti-MMP2 [4D3]
Invented by Ayham Alnabulsi from Vertebrate Antibodies Limited
Invented at Vertebrate Antibodies Limited
- Datasheet
- References (10)
- Inventor Info
Info
![Image for Anti-MMP2 [4D3]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,q_auto/b46010a0-c95d-4b5c-a9b4-e50ddeb49c8d.jpg)
![Image for Anti-MMP2 [4D3]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,q_auto/f4b9c338-49b2-41a8-9891-4a9462b611ae.jpg)
![Image for Anti-MMP2 [4D3]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,q_auto/fa8dc2fb-46b3-465c-be0e-553bab10ef1c.jpg)
![Immunohistochemistry was performed on FFPE sheep brain sections. The image shows positive immuno-staining using Anti-MMP2 [4D3]. The peptide immunogen used to generate the antibody is identical in mouse (Mus musculus), rat (Rattus norvegicus), sheep (Ovis aries), bovine (Bos taurus), dog (Canis familiaris), horse (Equus caballus) and chicken (gallus gallus).](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,q_auto/a651ecc4-3afc-49b7-b21a-9c08c7d1bd32.jpg)
![Image for Anti-MMP2 [4D3]](https://res.cloudinary.com/ximbio/image/upload/c_limit,fl_lossy,h_282,q_auto,w_368/b46010a0-c95d-4b5c-a9b4-e50ddeb49c8d.jpg)
![Image for Anti-MMP2 [4D3]](https://res.cloudinary.com/ximbio/image/upload/c_limit,fl_lossy,h_282,q_auto,w_368/f4b9c338-49b2-41a8-9891-4a9462b611ae.jpg)
![Image for Anti-MMP2 [4D3]](https://res.cloudinary.com/ximbio/image/upload/c_limit,fl_lossy,h_282,q_auto,w_368/fa8dc2fb-46b3-465c-be0e-553bab10ef1c.jpg)
![Immunohistochemistry was performed on FFPE sheep brain sections. The image shows positive immuno-staining using Anti-MMP2 [4D3]. The peptide immunogen used to generate the antibody is identical in mouse (Mus musculus), rat (Rattus norvegicus), sheep (Ovis aries), bovine (Bos taurus), dog (Canis familiaris), horse (Equus caballus) and chicken (gallus gallus).](https://res.cloudinary.com/ximbio/image/upload/c_limit,fl_lossy,h_282,q_auto,w_368/a651ecc4-3afc-49b7-b21a-9c08c7d1bd32.jpg)
![Image thumbnail for Anti-MMP2 [4D3]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/b46010a0-c95d-4b5c-a9b4-e50ddeb49c8d.jpg)
![Image thumbnail for Anti-MMP2 [4D3]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/f4b9c338-49b2-41a8-9891-4a9462b611ae.jpg)
![Image thumbnail for Anti-MMP2 [4D3]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/fa8dc2fb-46b3-465c-be0e-553bab10ef1c.jpg)
![Image thumbnail for Anti-MMP2 [4D3]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/a651ecc4-3afc-49b7-b21a-9c08c7d1bd32.jpg)
| Catalogue Number | 151619 |
| Applications | ELISA IHC IF IP WB |
| Antigen/Gene or Protein Targets | Human matrix metalloproteinase 2 (MMP-2) |
| Reactivity | Human |
| Relevance | MMP2 degrades type IV collagen and plays an important role in menstrual break down, regulation of vascularization, angiogenesis, and inflammatory response. Mutations of MMP2 are associated with Torg-Winchester syndrome. |
| Host | Mouse |
| Immunogen | Ovalbumin-conjugated synthetic peptide; TSLGLPPDVQRVD |
| Positive Control | IHC: formalin-fixed, paraffin-embedded lung containing intra-alveolar macrophageswestern blot: rhMMP-2, 400 ng per lane |
| Subclass | IgG1 |
| Myeloma Used | P3X63Ag8.653 |
| Strain | Balb/c |
| Notes | Does not cross react on Western blot: with MMP-1, -9. The antibody reacts with MMP3 |
| Research Area | Adhesion, Cancer, Cardiovascular, Epigenetics & Nuclear Signalling, Metabolism |
References: 10 entries
Jeffery et al. 2009. Histopathology. 54(7):820-8. PMID: 19635101.
The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers.
Europe PMC ID: 19635101
Lyall et al. 2006. Clin Cancer Res. 12(4):1184-91. PMID: 16489072.
Profiling markers of prognosis in colorectal cancer.
Europe PMC ID: 16489072
Curran et al. 2004. Clin Cancer Res. 10(24):8229-34. PMID: 15623598.
Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
Europe PMC ID: 15623598
Murray et al. 1998. Gut. 43(6):791-7. PMID: 9824606.
Matrix metalloproteinases and their inhibitors in gastric cancer.
Europe PMC ID: 9824606
Murray et al. 1998. J Pathol. 185(3):256-61. PMID: 9771478.
Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer.
Europe PMC ID: 9771478
Add a reference
References: 10 entries
Jeffery et al. 2009. Histopathology. 54(7):820-8. PMID: 19635101.
The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers.
Lyall et al. 2006. Clin Cancer Res. 12(4):1184-91. PMID: 16489072.
Profiling markers of prognosis in colorectal cancer.
Curran et al. 2004. Clin Cancer Res. 10(24):8229-34. PMID: 15623598.
Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
Murray et al. 1998. Gut. 43(6):791-7. PMID: 9824606.
Matrix metalloproteinases and their inhibitors in gastric cancer.
Murray et al. 1998. J Pathol. 185(3):256-61. PMID: 9771478.
Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer.
Add a reference
